Tag: Astellas

TOKYO – WEBWIRE – Friday, December 22, 2023 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, Astellas) announced today that it has completed the acquisition of Propella Therapeutics, Inc. (President and CEO: William Moore, Propella), and has become a wholly owned subsidiary of Astellas as of U.S. Eastern Time December 21, 2023. Through the acquisition of Propella, Astellas has acquired PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer. PRL-02 is a novel, long-acting prodrug* of abiraterone that, following intramuscular injection, is expected to achieve high concentrations in target tissues where ... Read more

TOKYO and KANAGAWA – WEBWIRE – Monday, July 24, 2023 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, Astellas) and PeptiDream Inc. (TSE: 4587, President and CEO: Patrick C. Reid, PeptiDream) today announced a research collaboration and license agreement to discover novel protein degraders for two targets selected by Astellas. Under the agreement between the two companies, Astellas will have the option to select up to three additional targets to be included in the collaboration. Astellas focuses on targeted protein degraders directed to undruggable targets that are difficult to approach with conventional technologies. Under the terms of the ... Read more

Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers TOKYO – WEBWIRE – Friday, June 9, 2023 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, Astellas) today announced the submission of a New Drug Application (NDA) on June 9, 2023 to Japans Ministry of Health, Labour and Welfare (MHLW) for zolbetuximab, a first-in-class investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive. If approved, zolbetuximab would be the ... Read more

Astellas Pharma Inc. (TSE: 4503), Eisai Co., Ltd. (TSE: 4523), Daiichi Sankyo Company, Limited (TSE: 4568) and Takeda Pharmaceutical Company Limited. (TSE: 4502/ NYSE:TAK) today announced that the four companies have agreed the collaboration to reduce environmental burden in the field of pharmaceutical packaging. Based on the agreement, the four companies will aim to promote the use of more environmentaly friendly packaging for pharmaceutical products by sharing knowledge on packaging technologies to reduce environmental burden, such as blister packs made of biomass-based plastic instead of petroleum-derived plastic, compact packaging, recycled packaging materials, and recyclable packaging materials. Astellas, Eisai, Daiichi Sankyo, ... Read more